Figure 3.

Clinical signs and inflammatory parameters in A129 mice infected by ZIKV treated or not with 1-MT inhibitor. (A) Experimental schematic representation of experimental strategy. A129 were inoculated (i.v) with 4x10³ PFU/200μL of ZIKV and treated daily with 1-MT. (B) The body weight was evaluated daily and (C) the intraocular pressure was analyzed on days 0, 3 and 5. At day 5 of infection, (D) the brain and (E) optical nerve was harvested for plaque assay analysis. (F) Measurement of myeloperoxidase activity (neutrophil accumulation) and (G–J) chemokine/cytokine production was assessed in mouse brain of animals. All results are expressed as mean and error bar indicate the standard error (SEM) and are representative of at least two independent experiments. Statistically significant differences were assessed by Two-way ANOVA plus Tukey’s comparisons test (A, B), Mann Whitney test (D, E) and One-way ANOVA (F–J) plus Tukey’s comparisons test. (##) for P < 0,01 and (####) for P < 0,0001 when compared to the MOCK group. (*) for P < 0,05 and (**) for P < 0,001 compared to the ZIKV group.